CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The RenTenTion project aims to develop a new generation of immune checkpoint inhibitors using smaller single domain antibodies. These antibodies target the immune suppressive cells in tumors, enhancing penetration and retention, ultimately improving cancer treatment efficacy.
Immune checkpoint inhibitors (ICIs) for cancer therapy have revolutionized the treatment of several cancers.
These ICIs are made from monoclonal antibodies that antagonize inhibitory signals via cytotoxic T-lymphocyte- associated antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) that block the tumoricidal activity of T cells.
Although these ICIs have improved the overall survival of cancer patients such as cutaneous melanoma patients, only one third of patients has remained progressi…
VRIJE UNIVERSITEIT BRUSSEL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Niel
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
